

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 May 2020 (28.05.2020)



(10) International Publication Number
WO 2020/106620 A1

(51) International Patent Classification:

A61P 35/02 (2006.01) A61K 39/00 (2006.01)
C07K 16/28 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2019/062011

(22) International Filing Date:

18 November 2019 (18.11.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/769,514 19 November 2018 (19.11.2018) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Rt. 206 & Province Line Road, Princeton, New
Jersey 08543 (US).

(72) Inventors: **YAMNIUK, Aaron**; c/o Bristol-Myers Squibb,
Route 206 & Province Line Road, Princeton, New Jer-
sey 08543 (US). **STRUTHERS, Mary**; c/o Bristol-My-
ers Squibb, Route 206 & Province Line Road, Princeton,
New Jersey 08543 (US). **KRYSTEK, Stanley R., Jr.**; c/
o Bristol-Myers Squibb, Route 206 & Province Line Road,
Princeton, New Jersey 08543 (US). **NAYEEM, Akbar**; c/
o Bristol-Myers Squibb, Route 206 & Province Line Road,
Princeton, New Jersey 08543 (US). **RAKESTRAW, Gin-
ger**; c/o Bristol-Myers Squibb, 100 Binney Street, Cam-
bridge, Massachusetts 02142 (US).

(74) Agent: **BRONWEN, M., Loeb** et al.; BRONWEN LOEB,
1500 K Street, N.W., Washington, District of Columbia
20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF

(57) Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.



WO 2020/106620 A1